Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy

Background and Objective Genetic polymorphisms of cytochrome P450 (CYP) 2C9 ( CYP2C9 ) and vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirements. At present, howeve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacokinetics 2012-12, Vol.51 (12), p.799-808
Hauptverfasser: Ichimura, Yosuke, Takahashi, Harumi, Lee, Michael T. M., Shiomi, Mari, Mihara, Kiyoshi, Morita, Takashi, Chen, Yuan-Tsong, Echizen, Hirotoshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 808
container_issue 12
container_start_page 799
container_title Clinical pharmacokinetics
container_volume 51
creator Ichimura, Yosuke
Takahashi, Harumi
Lee, Michael T. M.
Shiomi, Mari
Mihara, Kiyoshi
Morita, Takashi
Chen, Yuan-Tsong
Echizen, Hirotoshi
description Background and Objective Genetic polymorphisms of cytochrome P450 (CYP) 2C9 ( CYP2C9 ) and vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirements. At present, however, the factors associated with over-anticoagulation responses, especially before achieving the maintenance phase, have not been completely clarified. In this study, we investigated the effects of baseline coagulation activity assessed in terms of the level of fully carboxylated plasma normal prothrombin (NPT) on international normalized ratio (INR) control during the induction phase of warfarin therapy. Our objectives were to (1) identify factors associated with inter-patient variability in baseline NPT (NPT 0 ); (2) estimate the therapeutic NPT (NPT tx ) levels that can achieve an INR of 2–3; and (3) investigate the influence of NPT 0 on the INR response to warfarin by employing modelling and simulation techniques. Methods We measured NPT before (NPT 0 ) and during the introduction of warfarin therapy for up to 3 months and analysed functional single nucleotide polymorphisms (SNPs) of VKORC1 and CYP4F2 in 179 Chinese patients. The patients were classified into tertile groups according to NPT 0 values (i.e. high, intermediate and low groups), and in each group the NPT tx achieving therapeutic INR, the absolute reduction of NPT from NPT 0 to NPT tx , and the percentage inhibition of NPT 0 [{(NPT 0  − NPT tx )/NPT 0 } × 100] were obtained. The nonlinear relationship between NPT and INR was modelled on the basis of the INR value before warfarin treatment (INR 0 ) added by the nonlinear increase in INR after warfarin initiation, which was predicted using the percentage inhibition of NPT 0 and a nonlinear coefficient (λ). The population parameter λ and its inter-individual variability and intra-individual variability in INR in the NPT–INR model were estimated by nonlinear mixed-effect modelling software NONMEM ® . Results Multivariate analysis identified age and liver disease as covariates of NPT 0 , but none of the SNPs had a significant influence. Although the mean absolute NPT reduction necessary to achieve NPT tx was dependent on NPT 0 (i.e. the higher the NPT 0 , the larger the reduction in NPT), the percentage inhibition was within the narrow range of 67–72 % of NPT 0 , irrespective of NPT 0 . However, a significantly higher percentage inhibition (80 % on avera
doi_str_mv 10.1007/s40262-012-0009-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1220362650</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3145775971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-4bbe785631bd7d90c92d9e78f0bf6a030b6439fe3d3faabf34454f86080884ed3</originalsourceid><addsrcrecordid>eNp1kduK1TAUhoMoznb0AbyRgAjeVFcOTdvLme1pw6AgI16WtEnGDGlak1YYn8cHdXW6PSAYCAl_vvWvJD8hjxm8YADVyyyBK14AwwnQFOoO2TFWNQVruLpLdiDwpGyUOCEPcr5GpuYA98kJF8BqWcGO_DjE2abiEI3_5s2iA33lnbPJxt5m6iM919kGHy3dj_pqCXr2Y6Rn_Yz47BHR0dDLL9Ynehim4PtbIFM3orBax1sBfd-PadDBf7eGflw1NIxzGrHhkny8op91chp3WIbOWx80Tnq6eUjuOR2yfXRcT8mnN68v9--Kiw9vD_uzi6LHj5gL2XW2qkslWGcq00DfcNOg4qBzSoOATknROCuMcFp3TkhZSlcrqKGupTXilDzffKc0fl1sntvB596GoKMdl9wyzkEorkpA9Ok_6PW44GMDUlLJusTRIMU2qk9jzsm6dkp-0OmmZdCuEbZbhC1G2K4Rtgprnhydl26w5nfFr8wQeHYEdO51cEnH3uc_nKpEqeoSOb5xeVo_2Ka_rvjf7j8BJwO2KA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1464855559</pqid></control><display><type>article</type><title>Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Ichimura, Yosuke ; Takahashi, Harumi ; Lee, Michael T. M. ; Shiomi, Mari ; Mihara, Kiyoshi ; Morita, Takashi ; Chen, Yuan-Tsong ; Echizen, Hirotoshi</creator><creatorcontrib>Ichimura, Yosuke ; Takahashi, Harumi ; Lee, Michael T. M. ; Shiomi, Mari ; Mihara, Kiyoshi ; Morita, Takashi ; Chen, Yuan-Tsong ; Echizen, Hirotoshi</creatorcontrib><description>Background and Objective Genetic polymorphisms of cytochrome P450 (CYP) 2C9 ( CYP2C9 ) and vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirements. At present, however, the factors associated with over-anticoagulation responses, especially before achieving the maintenance phase, have not been completely clarified. In this study, we investigated the effects of baseline coagulation activity assessed in terms of the level of fully carboxylated plasma normal prothrombin (NPT) on international normalized ratio (INR) control during the induction phase of warfarin therapy. Our objectives were to (1) identify factors associated with inter-patient variability in baseline NPT (NPT 0 ); (2) estimate the therapeutic NPT (NPT tx ) levels that can achieve an INR of 2–3; and (3) investigate the influence of NPT 0 on the INR response to warfarin by employing modelling and simulation techniques. Methods We measured NPT before (NPT 0 ) and during the introduction of warfarin therapy for up to 3 months and analysed functional single nucleotide polymorphisms (SNPs) of VKORC1 and CYP4F2 in 179 Chinese patients. The patients were classified into tertile groups according to NPT 0 values (i.e. high, intermediate and low groups), and in each group the NPT tx achieving therapeutic INR, the absolute reduction of NPT from NPT 0 to NPT tx , and the percentage inhibition of NPT 0 [{(NPT 0  − NPT tx )/NPT 0 } × 100] were obtained. The nonlinear relationship between NPT and INR was modelled on the basis of the INR value before warfarin treatment (INR 0 ) added by the nonlinear increase in INR after warfarin initiation, which was predicted using the percentage inhibition of NPT 0 and a nonlinear coefficient (λ). The population parameter λ and its inter-individual variability and intra-individual variability in INR in the NPT–INR model were estimated by nonlinear mixed-effect modelling software NONMEM ® . Results Multivariate analysis identified age and liver disease as covariates of NPT 0 , but none of the SNPs had a significant influence. Although the mean absolute NPT reduction necessary to achieve NPT tx was dependent on NPT 0 (i.e. the higher the NPT 0 , the larger the reduction in NPT), the percentage inhibition was within the narrow range of 67–72 % of NPT 0 , irrespective of NPT 0 . However, a significantly higher percentage inhibition (80 % on average) was observed in patients with INR values exceeding 4.0. As the nonlinear coefficient λ in the developed model was dependent on NPT 0 (i.e. the higher the NPT 0 , the larger the nonlinear λ value), the simulated nonlinear NPT–INR curves were superimposable in the three respective NPT 0 groups, and the only difference was the starting median NPT 0 level. As a result, a steeper increase in the slope of the nonlinear NPT–INR curve might be expected in patients with a lower NPT 0 after initiation of warfarin. Conclusions The present study suggests that INR may be prolonged by warfarin nonlinearly as a function of the percentage inhibition of NPT 0 . Furthermore, these results indicate that NPT 0 may contribute to inter-individual variability in the INR response, and that patients with low NPT 0 may have the potential to show a sharp increase in INR during initiation therapy with warfarin.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.1007/s40262-012-0009-6</identifier><identifier>PMID: 23018470</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aged ; Anticoagulants - pharmacology ; Anticoagulants - therapeutic use ; Asian Continental Ancestry Group - genetics ; Biological and medical sciences ; Blood Coagulation - drug effects ; Cytochrome P-450 Enzyme System - genetics ; Cytochrome P450 Family 4 ; Female ; General pharmacology ; Humans ; Internal Medicine ; International Normalized Ratio ; Male ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Mixed Function Oxygenases - genetics ; Original Research Article ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Pharmacotherapy ; Polymorphism, Single Nucleotide ; Prothrombin - analysis ; Vitamin K Epoxide Reductases ; Warfarin - pharmacology ; Warfarin - therapeutic use</subject><ispartof>Clinical pharmacokinetics, 2012-12, Vol.51 (12), p.799-808</ispartof><rights>Springer International Publishing Switzerland 2012</rights><rights>2014 INIST-CNRS</rights><rights>Copyright Wolters Kluwer Health Adis International Dec 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-4bbe785631bd7d90c92d9e78f0bf6a030b6439fe3d3faabf34454f86080884ed3</citedby><cites>FETCH-LOGICAL-c402t-4bbe785631bd7d90c92d9e78f0bf6a030b6439fe3d3faabf34454f86080884ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40262-012-0009-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40262-012-0009-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26735685$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23018470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ichimura, Yosuke</creatorcontrib><creatorcontrib>Takahashi, Harumi</creatorcontrib><creatorcontrib>Lee, Michael T. M.</creatorcontrib><creatorcontrib>Shiomi, Mari</creatorcontrib><creatorcontrib>Mihara, Kiyoshi</creatorcontrib><creatorcontrib>Morita, Takashi</creatorcontrib><creatorcontrib>Chen, Yuan-Tsong</creatorcontrib><creatorcontrib>Echizen, Hirotoshi</creatorcontrib><title>Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><addtitle>Clin Pharmacokinet</addtitle><description>Background and Objective Genetic polymorphisms of cytochrome P450 (CYP) 2C9 ( CYP2C9 ) and vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirements. At present, however, the factors associated with over-anticoagulation responses, especially before achieving the maintenance phase, have not been completely clarified. In this study, we investigated the effects of baseline coagulation activity assessed in terms of the level of fully carboxylated plasma normal prothrombin (NPT) on international normalized ratio (INR) control during the induction phase of warfarin therapy. Our objectives were to (1) identify factors associated with inter-patient variability in baseline NPT (NPT 0 ); (2) estimate the therapeutic NPT (NPT tx ) levels that can achieve an INR of 2–3; and (3) investigate the influence of NPT 0 on the INR response to warfarin by employing modelling and simulation techniques. Methods We measured NPT before (NPT 0 ) and during the introduction of warfarin therapy for up to 3 months and analysed functional single nucleotide polymorphisms (SNPs) of VKORC1 and CYP4F2 in 179 Chinese patients. The patients were classified into tertile groups according to NPT 0 values (i.e. high, intermediate and low groups), and in each group the NPT tx achieving therapeutic INR, the absolute reduction of NPT from NPT 0 to NPT tx , and the percentage inhibition of NPT 0 [{(NPT 0  − NPT tx )/NPT 0 } × 100] were obtained. The nonlinear relationship between NPT and INR was modelled on the basis of the INR value before warfarin treatment (INR 0 ) added by the nonlinear increase in INR after warfarin initiation, which was predicted using the percentage inhibition of NPT 0 and a nonlinear coefficient (λ). The population parameter λ and its inter-individual variability and intra-individual variability in INR in the NPT–INR model were estimated by nonlinear mixed-effect modelling software NONMEM ® . Results Multivariate analysis identified age and liver disease as covariates of NPT 0 , but none of the SNPs had a significant influence. Although the mean absolute NPT reduction necessary to achieve NPT tx was dependent on NPT 0 (i.e. the higher the NPT 0 , the larger the reduction in NPT), the percentage inhibition was within the narrow range of 67–72 % of NPT 0 , irrespective of NPT 0 . However, a significantly higher percentage inhibition (80 % on average) was observed in patients with INR values exceeding 4.0. As the nonlinear coefficient λ in the developed model was dependent on NPT 0 (i.e. the higher the NPT 0 , the larger the nonlinear λ value), the simulated nonlinear NPT–INR curves were superimposable in the three respective NPT 0 groups, and the only difference was the starting median NPT 0 level. As a result, a steeper increase in the slope of the nonlinear NPT–INR curve might be expected in patients with a lower NPT 0 after initiation of warfarin. Conclusions The present study suggests that INR may be prolonged by warfarin nonlinearly as a function of the percentage inhibition of NPT 0 . Furthermore, these results indicate that NPT 0 may contribute to inter-individual variability in the INR response, and that patients with low NPT 0 may have the potential to show a sharp increase in INR during initiation therapy with warfarin.</description><subject>Aged</subject><subject>Anticoagulants - pharmacology</subject><subject>Anticoagulants - therapeutic use</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation - drug effects</subject><subject>Cytochrome P-450 Enzyme System - genetics</subject><subject>Cytochrome P450 Family 4</subject><subject>Female</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Mixed Function Oxygenases - genetics</subject><subject>Original Research Article</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prothrombin - analysis</subject><subject>Vitamin K Epoxide Reductases</subject><subject>Warfarin - pharmacology</subject><subject>Warfarin - therapeutic use</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kduK1TAUhoMoznb0AbyRgAjeVFcOTdvLme1pw6AgI16WtEnGDGlak1YYn8cHdXW6PSAYCAl_vvWvJD8hjxm8YADVyyyBK14AwwnQFOoO2TFWNQVruLpLdiDwpGyUOCEPcr5GpuYA98kJF8BqWcGO_DjE2abiEI3_5s2iA33lnbPJxt5m6iM919kGHy3dj_pqCXr2Y6Rn_Yz47BHR0dDLL9Ynehim4PtbIFM3orBax1sBfd-PadDBf7eGflw1NIxzGrHhkny8op91chp3WIbOWx80Tnq6eUjuOR2yfXRcT8mnN68v9--Kiw9vD_uzi6LHj5gL2XW2qkslWGcq00DfcNOg4qBzSoOATknROCuMcFp3TkhZSlcrqKGupTXilDzffKc0fl1sntvB596GoKMdl9wyzkEorkpA9Ok_6PW44GMDUlLJusTRIMU2qk9jzsm6dkp-0OmmZdCuEbZbhC1G2K4Rtgprnhydl26w5nfFr8wQeHYEdO51cEnH3uc_nKpEqeoSOb5xeVo_2Ka_rvjf7j8BJwO2KA</recordid><startdate>201212</startdate><enddate>201212</enddate><creator>Ichimura, Yosuke</creator><creator>Takahashi, Harumi</creator><creator>Lee, Michael T. M.</creator><creator>Shiomi, Mari</creator><creator>Mihara, Kiyoshi</creator><creator>Morita, Takashi</creator><creator>Chen, Yuan-Tsong</creator><creator>Echizen, Hirotoshi</creator><general>Springer International Publishing</general><general>Adis International</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>201212</creationdate><title>Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy</title><author>Ichimura, Yosuke ; Takahashi, Harumi ; Lee, Michael T. M. ; Shiomi, Mari ; Mihara, Kiyoshi ; Morita, Takashi ; Chen, Yuan-Tsong ; Echizen, Hirotoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-4bbe785631bd7d90c92d9e78f0bf6a030b6439fe3d3faabf34454f86080884ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Anticoagulants - pharmacology</topic><topic>Anticoagulants - therapeutic use</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation - drug effects</topic><topic>Cytochrome P-450 Enzyme System - genetics</topic><topic>Cytochrome P450 Family 4</topic><topic>Female</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Mixed Function Oxygenases - genetics</topic><topic>Original Research Article</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prothrombin - analysis</topic><topic>Vitamin K Epoxide Reductases</topic><topic>Warfarin - pharmacology</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ichimura, Yosuke</creatorcontrib><creatorcontrib>Takahashi, Harumi</creatorcontrib><creatorcontrib>Lee, Michael T. M.</creatorcontrib><creatorcontrib>Shiomi, Mari</creatorcontrib><creatorcontrib>Mihara, Kiyoshi</creatorcontrib><creatorcontrib>Morita, Takashi</creatorcontrib><creatorcontrib>Chen, Yuan-Tsong</creatorcontrib><creatorcontrib>Echizen, Hirotoshi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ichimura, Yosuke</au><au>Takahashi, Harumi</au><au>Lee, Michael T. M.</au><au>Shiomi, Mari</au><au>Mihara, Kiyoshi</au><au>Morita, Takashi</au><au>Chen, Yuan-Tsong</au><au>Echizen, Hirotoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy</atitle><jtitle>Clinical pharmacokinetics</jtitle><stitle>Clin Pharmacokinet</stitle><addtitle>Clin Pharmacokinet</addtitle><date>2012-12</date><risdate>2012</risdate><volume>51</volume><issue>12</issue><spage>799</spage><epage>808</epage><pages>799-808</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>Background and Objective Genetic polymorphisms of cytochrome P450 (CYP) 2C9 ( CYP2C9 ) and vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirements. At present, however, the factors associated with over-anticoagulation responses, especially before achieving the maintenance phase, have not been completely clarified. In this study, we investigated the effects of baseline coagulation activity assessed in terms of the level of fully carboxylated plasma normal prothrombin (NPT) on international normalized ratio (INR) control during the induction phase of warfarin therapy. Our objectives were to (1) identify factors associated with inter-patient variability in baseline NPT (NPT 0 ); (2) estimate the therapeutic NPT (NPT tx ) levels that can achieve an INR of 2–3; and (3) investigate the influence of NPT 0 on the INR response to warfarin by employing modelling and simulation techniques. Methods We measured NPT before (NPT 0 ) and during the introduction of warfarin therapy for up to 3 months and analysed functional single nucleotide polymorphisms (SNPs) of VKORC1 and CYP4F2 in 179 Chinese patients. The patients were classified into tertile groups according to NPT 0 values (i.e. high, intermediate and low groups), and in each group the NPT tx achieving therapeutic INR, the absolute reduction of NPT from NPT 0 to NPT tx , and the percentage inhibition of NPT 0 [{(NPT 0  − NPT tx )/NPT 0 } × 100] were obtained. The nonlinear relationship between NPT and INR was modelled on the basis of the INR value before warfarin treatment (INR 0 ) added by the nonlinear increase in INR after warfarin initiation, which was predicted using the percentage inhibition of NPT 0 and a nonlinear coefficient (λ). The population parameter λ and its inter-individual variability and intra-individual variability in INR in the NPT–INR model were estimated by nonlinear mixed-effect modelling software NONMEM ® . Results Multivariate analysis identified age and liver disease as covariates of NPT 0 , but none of the SNPs had a significant influence. Although the mean absolute NPT reduction necessary to achieve NPT tx was dependent on NPT 0 (i.e. the higher the NPT 0 , the larger the reduction in NPT), the percentage inhibition was within the narrow range of 67–72 % of NPT 0 , irrespective of NPT 0 . However, a significantly higher percentage inhibition (80 % on average) was observed in patients with INR values exceeding 4.0. As the nonlinear coefficient λ in the developed model was dependent on NPT 0 (i.e. the higher the NPT 0 , the larger the nonlinear λ value), the simulated nonlinear NPT–INR curves were superimposable in the three respective NPT 0 groups, and the only difference was the starting median NPT 0 level. As a result, a steeper increase in the slope of the nonlinear NPT–INR curve might be expected in patients with a lower NPT 0 after initiation of warfarin. Conclusions The present study suggests that INR may be prolonged by warfarin nonlinearly as a function of the percentage inhibition of NPT 0 . Furthermore, these results indicate that NPT 0 may contribute to inter-individual variability in the INR response, and that patients with low NPT 0 may have the potential to show a sharp increase in INR during initiation therapy with warfarin.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>23018470</pmid><doi>10.1007/s40262-012-0009-6</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0312-5963
ispartof Clinical pharmacokinetics, 2012-12, Vol.51 (12), p.799-808
issn 0312-5963
1179-1926
language eng
recordid cdi_proquest_miscellaneous_1220362650
source MEDLINE; SpringerLink Journals
subjects Aged
Anticoagulants - pharmacology
Anticoagulants - therapeutic use
Asian Continental Ancestry Group - genetics
Biological and medical sciences
Blood Coagulation - drug effects
Cytochrome P-450 Enzyme System - genetics
Cytochrome P450 Family 4
Female
General pharmacology
Humans
Internal Medicine
International Normalized Ratio
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Mixed Function Oxygenases - genetics
Original Research Article
Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions
Pharmacology. Drug treatments
Pharmacology/Toxicology
Pharmacotherapy
Polymorphism, Single Nucleotide
Prothrombin - analysis
Vitamin K Epoxide Reductases
Warfarin - pharmacology
Warfarin - therapeutic use
title Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A14%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inter-Individual%20Differences%20in%20Baseline%20Coagulation%20Activities%20and%20Their%20Implications%20for%20International%20Normalized%20Ratio%20Control%20During%20Warfarin%20Initiation%20Therapy&rft.jtitle=Clinical%20pharmacokinetics&rft.au=Ichimura,%20Yosuke&rft.date=2012-12&rft.volume=51&rft.issue=12&rft.spage=799&rft.epage=808&rft.pages=799-808&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.1007/s40262-012-0009-6&rft_dat=%3Cproquest_cross%3E3145775971%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1464855559&rft_id=info:pmid/23018470&rfr_iscdi=true